bioRxivCell BiologyPreprint
Non-cell autonomous cardiomyocyte regulation complicates gene supplementation therapy for LMNA cardiomyopathy
Y. Sun, C. Guo, Z. Chen, J. Lin, L. Yang, Y. Zhang, C. Wu, D. Zhao, B. Jardin, W. Pu, M. Zhao, E. Dong, X. Hu, S. Zhang, Y. Guo
Abstract
AimsRecombinant adeno-associated viruses (rAAVs) are federally approved gene delivery vectors for in vivo gene supplementation therapy. Loss-of-function truncating variants of LMNA, the coding gene for Lamin-A/C, are one of the primary causes of inherited dilate cardiomyopathy (DCM). Here we aim to study whether AAV-based LMNA supplementation could treat LMNA deficiency-triggered cardiac defects. Methods and ResultsWe compared whole-body, cardiomyocyte-specific and genetic-mosaic mouse models that carry Lmna truncating variants at the same genetic loci and uncovered primarily a non-cell autonomous impact of Lmna on cardiomyocyte maturation. Whole-body lamin-A supplementation by rAAVs moderately rescued the cardiac defects in Lmna germline mutants. By contrast, cardiomyocyte-specific lamin-A addback failed to restore the cardiomyocyte growth defects. A Cre-loxP-based AAV vector that expresses lamin-A throughout the body but excluding the heart was able to restore cardiomyocyte growth in Lmna germline mutants. ConclusionsLmna regulates cardiomyocyte growth non-cell autonomously. Non-myocytes are the key cell targets for a successful gene therapy for LMNA-associated cardiac defects. Translational perspectiveLMNA truncating mutations are among the major causes of inherited DCM. AAV gene supplementation therapy is emerging as a promising strategy to treat genetic cardiomyopathy, but whether this strategy is suitable for LMNA cardiomyopathy remained unclear. Our study counterintuitively showed that the cardiomyocytes are not necessarily the correct therapeutic cell targets for AAV-based treatment of LMNA cardiomyopathy. By contrast, careful elucidation of cell-autonomous versus non-cell-autonomous gene functions is essential for the proper design of a gene supplementation therapy for cardiomyopathy. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=189 SRC="FIGDIR/small/549413v1_ufig1.gif" ALT="Figure 1"> View larger version (42K): org.highwire.dtl.DTLVardef@37cfdaorg.highwire.dtl.DTLVardef@2f2cd1org.highwire.dtl.DTLVardef@1278d08org.highwire.dtl.DTLVardef@19c4869_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: mouse
- research focus: cell type annotation
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: cell-cell communication
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Allele-specific silencing ameliorates restrictive cardiomyopathy due to a human myosin regulatory light chain mutation
Kathia Zaleta-Rivera, Alexandra Dainis, … Euan Angus Ashley·CirculationPeer-reviewed·Jul 18, 2019
- Nuclear envelope rupture in cardiomyocytes orchestrates early transcriptomic changes and immune activation in LMNA-related dilated cardiomyopathy that are reversed by LINC complex disruption
Noam Zuela-Sopilniak, Julien L. P. Morival, … Jan Lammerding·bioRxiv·Jun 11, 2024
- Perinuclear damage from nuclear envelope deterioration elicits stress responses that contribute to LMNA cardiomyopathy
K. Sikder, E. Phillips, … J. C. Choi·bioRxiv·Feb 14, 2023
- RNA polymerase loss by nuclear rupture drives LMNA cardiomyopathy
Atsuki En, Melanie E. Gucwa, … Kohta Ikegami·bioRxiv·Apr 4, 2026
- The Mutated p.H222P A-type Lamins Drive Loxl2-Mediated Extracellular Matrix Remodeling in Both Patient-Derived Cardiomyocytes and Mouse Models of Dilated Cardiomyopathy
Marie Kervella, Cécile Peccate, … Antoine Muchir·bioRxiv·Jan 10, 2025
- A highly penetrant LMNA R541C variant associated with dilated cardiomyopathy leads to dysregulation in metabolism and proliferation pathways in stem cell-derived cardiomyocytes
Thomas Keller, Ci Koehring, … Thomas V. McDonald·bioRxiv·Jul 29, 2026